Key facts
- It has raised $3.5M; the latest was Later Stage VC in Oct 2024.
- Notable investors include Rockstart, Brabantse Ontwikkelings Maatschappij, Fredriks family, Blue Tulip Awards, EchiumBio Holding — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for RiboPro
- ·The full record, as it builds
Funding rounds
No funding rounds for RiboPro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RiboPro
Developer of ribonucleic acid products designed to be used as research tools and therapeutics. The company uses proprietary technologies including de-immunization of mRNA (messenger ribonucleic acid), expression boosting and prolonging libraries, and novel LNP (lipid nanoparticle) compositions for delivery to a variety of tissues, enabling researchers to seamlessly integrate RNA into their projects while ensuring reliable quality and performance.
- Sector
- Healthcare
- HQ
- Oss, Netherlands
- Founded
- 2020
- Employees
- 35
- Website
- ribopro.eu/
- Ownership
- Privately Held (backing)
RiboPro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RiboPro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RiboPro in its N-PORT filings yet. We sweep new filings monthly.